Literature DB >> 14649556

Neurofibromatosis 2 in the pediatric population.

Fabio Nunes1, Mia MacCollin.   

Abstract

Neurofibromatosis 2 is a severe autosomal dominant disorder characterized by the occurrence of bilateral vestibular schwannomas and other benign tumors of the nervous system. Excellent natural history studies exist for adults with neurofibromatosis 2, but limited outcome data are available for children with neurofibromatosis 2. In this study, we present clinical data on 12 patients with neurofibromatosis 2 and age at diagnosis before 18 years. Full record review included surgical reports, pathology reports, and imaging studies; all patients were personally examined by a single author. One third of the patients presented with hearing impairment and another third presented with other cranial nerve dysfunction. Tumor load was extensive, including cranial meningiomas in 75%, cranial schwannomas other than vestibular schwannomas in 83%, and spinal cord tumors in 75%. Family history was present in two thirds of the patients. Surgical removal of vestibular schwannomas was performed in 58%; none had full preservation of hearing postsurgery. Functionally, 75% of children had hearing loss, 83% had visual impairment, 25% had abnormal ambulation, and 25% were performing below grade level. In conclusion, increased clinical awareness, better imaging techniques, and molecular diagnostics have made pediatric diagnosis of neurofibromatosis 2 feasible, but outcomes appear to be worse than in adult patients. Further work is needed to determine optimal management of pediatric neurofibromatosis 2.

Entities:  

Mesh:

Year:  2003        PMID: 14649556     DOI: 10.1177/08830738030180101301

Source DB:  PubMed          Journal:  J Child Neurol        ISSN: 0883-0738            Impact factor:   1.987


  12 in total

1.  Consensus recommendations for current treatments and accelerating clinical trials for patients with neurofibromatosis type 2.

Authors:  Jaishri O Blakeley; D Gareth Evans; John Adler; Derald Brackmann; Ruihong Chen; Rosalie E Ferner; C Oliver Hanemann; Gordon Harris; Susan M Huson; Abraham Jacob; Michel Kalamarides; Matthias A Karajannis; Bruce R Korf; Victor-Felix Mautner; Andrea I McClatchey; Harry Miao; Scott R Plotkin; William Slattery; Anat O Stemmer-Rachamimov; D Bradley Welling; Patrick Y Wen; Brigitte Widemann; Kim Hunter-Schaedle; Marco Giovannini
Journal:  Am J Med Genet A       Date:  2011-12-02       Impact factor: 2.802

Review 2.  Neurofibromatosis type 2.

Authors:  Ashok R Asthagiri; Dilys M Parry; John A Butman; H Jeffrey Kim; Ekaterini T Tsilou; Zhengping Zhuang; Russell R Lonser
Journal:  Lancet       Date:  2009-05-22       Impact factor: 79.321

3.  Introduction to phacomatoses (neurocutaneous disorders) in childhood.

Authors:  Martino Ruggieri; Agata Polizzi; Gioacchino Paolo Marceca; Stefano Catanzaro; Andrea D Praticò; Concezio Di Rocco
Journal:  Childs Nerv Syst       Date:  2020-09-17       Impact factor: 1.475

4.  Clinicopathologic assay of 15 tumor resections in a family with neurofibromatosis type 2.

Authors:  Salvatore Di Maio; Goran Mrak; Gordana Juric-Sekhar; Donald Born; Alessandra Mantovani; Laligam N Sekhar
Journal:  J Neurol Surg B Skull Base       Date:  2012-04

5.  Early Genetic Diagnosis of Neurofibromatosis Type 2 From Skin Plaque Plexiform Schwannomas in Childhood.

Authors:  Elisabeth Castellanos; Adrià Plana; Cristina Carrato; Meritxell Carrió; Inma Rosas; Emilio Amilibia; Francesc Roca-Ribas; Cristina Hostalot; Alicia Castillo; Andrea Ros; Ariadna Quer; Juan Luis Becerra; Hector Salvador; Conxi Lázaro; Ignacio Blanco; Eduard Serra; Isabel Bielsa
Journal:  JAMA Dermatol       Date:  2018-03-01       Impact factor: 10.282

6.  Therapeutics for childhood neurofibromatosis type 1 and type 2.

Authors:  Simone L Ardern-Holmes; Kathryn N North
Journal:  Curr Treat Options Neurol       Date:  2011-12       Impact factor: 3.598

7.  A Prospective Evaluation of Swallowing and Speech in Patients with Neurofibromatosis Type 2.

Authors:  Sibi Rajendran; Joseph Antonios; Beth Solomon; H Jeffrey Kim; Tianxia Wu; James Smirniotopoulos; Gretchen Scott; Sarah Benzo; Christina Hayes; John D Heiss; Prashant Chittiboina
Journal:  J Neurol Surg B Skull Base       Date:  2019-09-18

8.  Genotype-phenotype correlations for nervous system tumors in neurofibromatosis 2: a population-based study.

Authors:  Michael E Baser; Lisa Kuramoto; Harry Joe; J M Friedman; Andrew J Wallace; James E Gillespie; Richard T Ramsden; D Gareth R Evans
Journal:  Am J Hum Genet       Date:  2004-06-09       Impact factor: 11.025

Review 9.  Natural history of neurofibromatosis type 2 with onset before the age of 1 year.

Authors:  Martino Ruggieri; Anna Lia Gabriele; Agata Polizzi; Vincenzo Salpietro; Francesco Nicita; Piero Pavone; Nunzio Platania; Pietro Milone; Angela Distefano; Giuseppe Privitera; Giuseppe Belfiore; Francesca Granata; Rosario Caltabiano; Vincenzo Albanese; Lorenzo Pavone; Aldo Quattrone
Journal:  Neurogenetics       Date:  2013-02-03       Impact factor: 2.660

10.  Bevacizumab treatment for meningiomas in NF2: a retrospective analysis of 15 patients.

Authors:  Fabio P Nunes; Vanessa L Merker; Dominique Jennings; Paul A Caruso; Emmanuelle di Tomaso; Alona Muzikansky; Fred G Barker; Anat Stemmer-Rachamimov; Scott R Plotkin
Journal:  PLoS One       Date:  2013-03-21       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.